OurCrowd portfolio company ReWalk was featured in Globes, the leading Israeli financial daily. ReWalk is the developer of the FDA-approved ReWalk exoskeleton device, providing paraplegics with an independent, natural walking experience that provides them numerous social, psychological, and physical benefits.

The graph of Israeli company ReWalk Robotics Ltd.’s (Nasdaq:RWLK) share price is a good place for beginning the company’s story. ReWalk, which has developed an external skeleton enabling people with spinal cord injuries to walk, held its Nasdaq IPO in September 2014, two months after obtaining US Food and Drug Administration (FDA) approval for its product. The offering share price was $12. Over the ensuing 15 months, the share price declined slowly and consistently to a low point of less than $6. Two weeks ago came a total turnaround: the share price skyrocketed 90% in a single day, and has now reached almost $14.50, almost 140% above its low point.

ReWalk raised $1,320,000 from OurCrowd investors in June 2013.

Read more on Globes here.